Taizhou, or “peaceful prefecture” in Mandarin, is a city with a history of over 2,100 years that has not undergone a name change in the past two centuries despite a modification of its prefecture jurisdiction.
For in depth analysis of Cambodian Business, visit Capital Cambodia
Taizhou’s earliest jurisdiction was established in the Spring and Autumn Period. In the Eastern Jin Dynasty, the town experienced an economic boom and a substantial salt trade that made it the home of many wealthy merchants.
Taizhou City is one of Jiangsu thirteen prefecture-level cities which administer two old municipal districts and for county-level cities: Jingjiang, Jiangyan, Taixing, and Xinghua.
Dubbed ‘China’s medical city’, it is a national hub hosting dozens of major international and domestic corporations involved in pharmaceutical, biomedical, biochemical and bio-tech.
Taizhou’s China Medical City (CMC) has attracted major international and domestic corporations who have established their subsidiaries and facilities here since its establishment in 2010. To date, more than 800 pharmaceutical giants have businesses and incubation centres located in this specialised city.
They include Nestlé, AstraZeneca, Takeda Pharmaceutical, Boehringer-Ingelheim, CSPC Pharmaceutical Group and Neptunus Pharmaceutical, as well as home grown pharmaceutical giant Yangtze River Pharmaceutical Company.
The city has more than 60 domestic and foreign universities as well as medical R&D institutions which generated 1,000 innovative pharmaceutical solutions, which in turn attracted more than 2,800 skilled workers at home and abroad.
These enterprises are mainly involved in research or manufacture in the pharmaceutical, biomedical, biochemical and bio-tech fields, as well as pioneer projects, such as stem cell research. It is also China’s largest producer of pharmaceuticals.
CMC director Zhu Laidong said major international and domestic corporations have settled their subsidiaries and facilities in this area, and CMC has also established a representative office in the United Kingdom.
“The UK incubator in London is CMC’s third overseas facility, after the US and Germany. It serves as a regular office for meetings between Chinese and British life science companies, regulators and investors.
“Since its inception and construction, CMC is committed to create China’s largest and most comprehensive bio-medical industry based on the concept of revitalising cities with industry, promoting economic activity, integrating cities and industry, and achieving prosperity,” Mr Zhu pointed out.
He added that CMC’s biggest allure is its existing collaboration with Chinese regulators, including the Ministry of Health, the China Food and Drug Administration and the State Administration of Traditional Chinese Medicine.
It also collaborates with the US’s Food and Drug Administration, as well as major drug research and development centres and certification authorities.
“Inspectors from various international drug authorities often call on the factories here for surprise checks to ensure that pharmaceuticals produced within the city are up to international safety standards and abide to Good Manufacturing Practice,” he said.
According to Mr Zhu, what made CMC attractive to giant pharmaceutical companies is its established ecosystem, including its collection of life science companies and talent in the industry.
CMC is the first government-backed, national-level medical incubator to be established with the objective of attracting more international medical companies to commercialise and manufacture their products in China.
It was set up in 2010 through the joint efforts of several government agencies, including the Ministry of Technology, the Ministry of Health, the China Food and Drug Administration and the State Administration of Traditional Chinese Medicine.